Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGCNASDAQ:CLYMNASDAQ:IVANASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.31+7.9%$1.29$0.77▼$8.65$239.94M0.797.79 million shs7.37 million shsCLYMClimb Bio$1.32+1.9%$1.23$1.05▼$9.58$88.86M-0.12271,063 shs7,492 shsIVAInventiva$3.43-5.2%$3.35$1.53▼$4.05$328.12M0.7564,070 shs567 shsTKNOAlpha Teknova$5.87+2.1%$5.96$1.16▼$10.37$313.70M0.5397,274 shs35,403 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth0.00%-28.82%-9.02%-3.20%-84.91%CLYMClimb Bio+9.32%+10.26%+1.57%-8.51%+128,999,900.00%IVAInventiva+6.78%+6.94%+7.10%+27.69%-3.21%TKNOAlpha Teknova+0.35%-2.04%-11.81%-3.69%+212.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth2.2126 of 5 stars2.52.00.00.02.20.01.3CLYMClimb Bio2.987 of 5 stars3.70.00.00.02.22.51.3IVAInventiva2.2593 of 5 stars3.43.00.00.01.51.70.6TKNOAlpha Teknova1.8705 of 5 stars3.51.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.00Sell$2.0053.26% UpsideCLYMClimb Bio 3.33Buy$8.50546.39% UpsideIVAInventiva 2.80Moderate Buy$10.40203.21% UpsideTKNOAlpha Teknova 3.00Buy$8.5044.80% UpsideCurrent Analyst Ratings BreakdownLatest CLYM, CGC, IVA, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.004/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/28/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$269.00M0.89N/AN/A$2.72 per share0.48CLYMClimb BioN/AN/AN/AN/A$3.90 per shareN/AIVAInventiva$9.20M35.67N/AN/A($0.67) per share-5.12TKNOAlpha Teknova$38.25M8.20N/AN/A$2.21 per share2.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$487.23M-$4.04N/AN/AN/A-156.98%-56.52%-24.18%8/7/2025 (Estimated)CLYMClimb Bio-$35.12M-$2.38N/AN/AN/AN/A-42.21%-41.39%8/13/2025 (Estimated)IVAInventiva-$119.51MN/A0.00N/AN/AN/AN/AN/AN/ATKNOAlpha Teknova-$36.78M-$0.48N/AN/AN/A-87.17%-35.30%-24.52%N/ALatest CLYM, CGC, IVA, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million5/14/2025Q1 2025CLYMClimb Bio-$0.15-$0.31-$0.16-$0.31N/AN/A5/8/2025Q1 2025TKNOAlpha Teknova-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million3/25/2025Q4 2024CLYMClimb Bio-$0.15-$0.13+$0.02-$0.13N/AN/A3/4/2025Q4 2024TKNOAlpha TeknovaN/A-$0.11N/A-$0.11$9.10 million$9.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.743.522.58CLYMClimb BioN/A57.7357.73IVAInventivaN/A0.590.59TKNOAlpha Teknova0.124.733.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%CLYMClimb Bio69.76%IVAInventiva19.06%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth1.30%CLYMClimb Bio0.80%IVAInventiva32.00%TKNOAlpha Teknova15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150183.87 million153.39 millionOptionableCLYMClimb Bio967.58 million65.07 millionN/AIVAInventiva10095.66 million35.68 millionNot OptionableTKNOAlpha Teknova24053.44 million45.21 millionNot OptionableCLYM, CGC, IVA, and TKNO HeadlinesRecent News About These Companies61,811 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Acquired by Jane Street Group LLCMay 31, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Makes New Investment in Alpha Teknova, Inc. (NASDAQ:TKNO)May 22, 2025 | marketbeat.comAlpha Teknova, Inc. (NASDAQ:TKNO) Stake Reduced by Schonfeld Strategic Advisors LLCMay 17, 2025 | marketbeat.comSusquehanna International Group LLP Buys 172,828 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)May 13, 2025 | marketbeat.comAlpha Teknova (NASDAQ:TKNO) Posts Earnings ResultsMay 12, 2025 | marketbeat.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comAlpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comRaymond James Financial Inc. Invests $716,000 in Alpha Teknova, Inc. (NASDAQ:TKNO)May 9, 2025 | marketbeat.comTeknova Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.com683 Capital Management LLC Acquires New Shares in Alpha Teknova, Inc. (NASDAQ:TKNO)May 4, 2025 | marketbeat.comAlpha Teknova (TKNO) Traded Lower on Increased UncertaintyApril 30, 2025 | msn.comAlpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comTeknova to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAlpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation systemMarch 20, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | globenewswire.comTeknova, Pluristyx announce collaboration over next-generation cell therapiesMarch 11, 2025 | markets.businessinsider.comTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesMarch 11, 2025 | globenewswire.comEarnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67March 8, 2025 | uk.finance.yahoo.comBTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)March 6, 2025 | markets.businessinsider.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Why Carnival Could Be the Ultimate Non-Tech Growth StockBy Jeffrey Neal Johnson | May 22, 2025View Why Carnival Could Be the Ultimate Non-Tech Growth StockCarnival's Comeback: Is the Stock Set for a Profitable Journey?By Jeffrey Neal Johnson | May 14, 2025View Carnival's Comeback: Is the Stock Set for a Profitable Journey?CLYM, CGC, IVA, and TKNO Company DescriptionsCanopy Growth NASDAQ:CGC$1.30 +0.10 (+7.85%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Climb Bio NASDAQ:CLYM$1.32 +0.03 (+1.94%) As of 10:30 AM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Inventiva NASDAQ:IVA$3.43 -0.19 (-5.25%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Alpha Teknova NASDAQ:TKNO$5.87 +0.12 (+2.09%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
